We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tiens Biotech Grp. (Usa) Common Stock | AMEX:TBV | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Chunchun Yu
Tianshi Group Co., Ltd
No. 17,
Xinyuan Road,
Wuqing New Tech Industrial Park
Tianjin, China
(86) 22-82137442 Phone
(86) 22-82118241 Fax
|
Douglas Freeman
O’Melveny & Myers LLP
31st Floor
AIA Central
1 Connaught Road Central
Hong Kong S.A.R.
(852) 3512-2300 Phone
(852) 2522-1760 Fax
|
o
|
a.
|
The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14-C or Rule 13e-3(c) under the Securities Exchange Act of 1934.
|
||
o
|
b.
|
The filing of a registration statement under the Securities Act of 1933.
|
||
o
|
c.
|
A tender offer.
|
||
þ
|
d.
|
None of the above.
|
Transaction Valuation*
|
Amount of Filing Fee**
|
||||
$
6,026,167.92
|
$699.64***
|
||||
*
|
The transaction valuation is estimated solely for purposes of calculating the filing fee pursuant to Rule 0-11(b) under the Securities Exchange Act of 1934, as amended. The calculation assumes the purchase of all outstanding shares of the Issuer (other than the 67,830,000 shares already beneficially owned by the Filing Persons) at a purchase price of $1.72 in cash per share. There were 3,503,586 shares of Common Stock of Tiens Biotech Group (USA), Inc. outstanding that were not beneficially owned by the Filing Persons as of June 24, 2011.
|
|
**
|
The amount of the filing fee is calculated in accordance with Regulation 240.0-11 of the Exchange Act. The fee is calculated by multiplying the transaction valuation by .00011610.
|
|
***
|
Previously paid.
|
|
o
|
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
Exhibit
|
||
Number
|
Description
|
|
(a)(1)
|
Letter from Tiens Biotech Group, Inc to Stockholders of Tiens Biotech Group (USA), Inc. *
|
|
(a)(2)
|
Form of Notice of Merger and Appraisal Rights *
|
|
(b)
|
None
|
|
(c)(1)
|
Letter Summarizing the Valuation Analysis Performed by Piper Jaffray & Co. dated June 20, 2011*
|
|
(c)(2)
|
Discussion Materials dated June 20, 2011 prepared for the Board of Directors of Tiens (USA) Investment Holdings Group Overseas Limited by Piper Jaffray & Co.*
|
|
(d)
|
Contribution Agreement by and between Tiens Biotech Group, Inc. and Tiens (USA) Investment Holdings Group Overseas Limited dated June 27, 2011*
|
|
(f)
|
Delaware General Corporation Law Section 262 — Appraisal Rights*
|
|
(g)
|
None
|
*
|
Previously filed
|
TIENS BIOTECH GROUP, INC.
|
||||
By:
|
/s/ Jinyuan Li
|
|||
Name:
|
Jinyuan Li
|
|||
Title:
|
President
|
|||
TIENS (USA) INVESTMENT HOLDINGS GROUP OVERSEAS LIMITED
|
||||
By:
|
/s/ Jinyuan Li
|
|||
Name:
|
Jinyuan Li
|
|||
Title:
|
Director
|
|||
TIENS INTERNATIONAL INVESTMENT HOLDINGS GROUP LIMITED
|
||||
By:
|
/s/ Jinyuan Li
|
|||
Name:
|
Jinyuan Li
|
|||
Title:
|
Director
|
|||
TIENS INVESTMENT HOLDINGS GROUP LIMITED
|
||||
By:
|
/s/ Jinyuan Li
|
|||
Name:
|
Jinyuan Li
|
|||
Title:
|
Authorized Person
|
|||
JINYUAN LI
|
||||
/s/ Jinyuan Li
|
||||
1 Year Tiens Biotech GR Usa Chart |
1 Month Tiens Biotech GR Usa Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions